[12] Patent
[11] Patent No.:GC0011350  
[45] Date of Publishing the Grant of the Patent: 31/Jul /2020                72/2020  
Number of the Decision to Grant the Patent:2020/170246
Date of the Decision to Grant the Patent:02/Jul/2020

[21] Application No.:GC 2014-27233

[22] Filing Date:26/5/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
PCT
27/5/2013
PCT/CN2013/076281

[72] Inventors:1- Johannes Aebi،2- Kurt Amrein،3- Wenming Chen،4- Benoit Hornsperger،5- Bernd Kuhn،6- Yongfu Liu،7- Hans P . Maerki،8- Rainer E. Martin،9- Alexander V . Mayweg،10- Xuefei Tan،11- Lisha Wang،12- Mingwei Zhou

[73] Owner: F. Hoffmann - La Roche AG, 124 Grenzacherstrasse , Basle, CH-4070, Switzerland

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: A61K 31/4439, 31/4545, 31/4725; A61P 5/42; C07D 401/14 (2006.01)

[56] Cited Documents:

-US 2013/072679 A1 (AEBI JOHANNES [CH] ET AL) 21 March 2013
-US 2011/118241 A1 (HARTMANN ROLF w [DE] ET AL) 19 May 2011
 
Examiner: PH. Bashair Z. AlEnizi

[54] NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS
[57] Abstract: The invention provides novel compounds having the general formula (I) (I)wherein R1, R2, R3, R4¸ R5, R6, R7, R8, R9, R10¸ R11, R12, R13, R14, R15, A, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
No. of claims: 15


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.